(MENAFN- Straits Research)
Immunoprotein Diagnostic Testing Market Size
The global immunoprotein diagnostic testing market size was valued at USD 10.39 billion in 2025 and is projected to grow from USD 11.07 billion in 2026 to USD 18.38 billion by 2034, registering a CAGR of 6.54% during the forecast period from 2026 to 2034. North America dominated the immunoprotein diagnostic testing market with a market share of 38.5% in 2025.
Immunoprotein Diagnostic Testing (ICI) refers to a specialized diagnostic approach that utilizes immunological methods to detect and analyze specific proteins in the body. These tests play a crucial role in diagnosing various conditions, including infectious and chronic diseases like cancer, by providing personalized results that guide appropriate treatment plans.
The major factors driving the growth of the ICI market include the rising prevalence of infectious and chronic diseases, such as cancer, advancements in screening technologies, a growing geriatric population, and the expansion of healthcare infrastructure. Cancer, being one of the most prevalent chronic diseases, is a major contributor to the market's expansion.
Immunoprotein Diagnostic Testing Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 10.39 Billion
2026 Market Size: USD 11.07 Billion
2034 Projected Market Size: USD 18.38 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 6.54%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 38.5%
Fastest-Growing Region: Asia-Pacific
Asia-Pacific CAGR (2026–2034): 8.12%
Segment Insights
By Product Type
Leading Segment: Kits & Reagents
Market Share in 2025: 58.9%
By Technology
Fastest-Growing Segment: Chemiluminescence Assay
CAGR: 7.48% (2026–2034)
By Application
Leading Segment: Oncology
Market Share in 2025: 27.4%
By End User
Fastest-Growing Segment: Diagnostic Laboratories
CAGR: 7.14% (2026–2034)
Download a Free Sample To learn more about this report,
Immunoprotein Diagnostic Testing Market Trends
Growing Adoption of Automated and High-Sensitivity Immunoprotein Testing Technologies
The immunoprotein diagnostic testing market is witnessing significant growth as clinical laboratories and healthcare providers increasingly adopt automated systems for measuring specific proteins associated with immune function, inflammation, infections, and chronic diseases. Advances in immunoassays, nephelometry, turbidimetry, and high-sensitivity testing technologies are enabling laboratories to improve analytical accuracy while processing larger sample volumes. Growing demand for early disease detection and monitoring of autoimmune, cardiovascular, and infectious conditions is encouraging manufacturers to expand immunoprotein assay menus and integrated diagnostic platforms. Laboratory automation and digital data management are further improving workflow efficiency and result consistency. These developments are strengthening protein-based disease assessment and contributing to overall immunoprotein diagnostic testing market growth.
In July 2025, Siemens Healthineers expanded its Atellica laboratory diagnostics portfolio with additional high-sensitivity immunoassay capabilities designed to improve automated testing efficiency and clinical decision support. This development strengthened advanced immunoprotein testing capabilities and reflected positive Immunoprotein Diagnostic Testing Market analysis.
Immunoprotein Diagnostic Testing Market Dynamics
Market Drivers
Rising Prevalence of Chronic and Immune-Related Diseases
The immunoprotein diagnostic testing market is witnessing steady growth as healthcare providers increasingly use protein biomarkers to diagnose and monitor autoimmune disorders, infectious diseases, cardiovascular conditions, cancers, and other chronic illnesses. Tests measuring immunoglobulins, complement proteins, C-reactive protein, free light chains, and other immunoproteins provide valuable information regarding immune activity, inflammation, and disease progression. Growing prevalence of chronic diseases and increasing demand for early diagnosis are supporting higher testing volumes across hospitals and diagnostic laboratories. Advances in automated immunoassay systems are further improving laboratory throughput, analytical accuracy, and turnaround times while enabling healthcare providers to process larger numbers of patient samples efficiently.
In March 2025, Siemens Healthineers expanded its laboratory diagnostics capabilities with advanced automated immunoassay technologies designed to improve testing efficiency and support growing demand for disease-specific biomarker analysis.
Market Restraints
High Cost of Advanced Diagnostic Systems and Reagents
The immunoprotein diagnostic testing market faces restraints from the costs associated with automated analyzers, specialized reagents, calibration materials, laboratory infrastructure, and routine quality-control procedures. Smaller diagnostic laboratories and healthcare facilities in developing regions may have limited budgets for installing sophisticated immunodiagnostic platforms. Reagent dependency and recurring consumable expenses can further increase overall testing costs. Laboratories must also employ trained personnel and follow strict procedures to maintain analytical accuracy and reproducibility. Differences in healthcare reimbursement and limited access to advanced diagnostic infrastructure can restrict testing availability, particularly in underserved regions where centralized laboratories remain concentrated in major urban areas.
In June 2025, diagnostic laboratories and equipment manufacturers continued investing in automated immunoassay platforms and laboratory workflow solutions, highlighting the significant infrastructure and operational requirements associated with high-throughput immunoprotein testing.
Market Opportunities
Expansion of Automated and Multiplex Immunodiagnostic Technologies
The immunoprotein diagnostic testing market offers significant opportunities through automation, multiplex assays, advanced biomarker panels, and digitally connected laboratory systems. Multiplex technologies can simultaneously measure several proteins from a single patient sample, potentially reducing sample requirements and improving diagnostic efficiency. Integration of artificial intelligence and advanced data analytics can further support interpretation of complex biomarker patterns and improve disease-risk assessment. Growing interest in personalized medicine also creates opportunities for immunoprotein testing to support patient stratification and treatment monitoring. Expansion of diagnostic infrastructure across emerging markets and development of compact automated analyzers can further increase access to sophisticated immunoprotein testing outside large centralized laboratories.
In July 2025, Roche continued expanding its automated diagnostic portfolio and integrated laboratory solutions, supporting broader adoption of high-throughput biomarker and immunoassay testing across clinical laboratories.
Market Challenges
Maintaining Test Accuracy and Standardization Across Diagnostic Platforms
The immunoprotein diagnostic testing market faces challenges in ensuring consistent analytical performance across different laboratories, instruments, reagents, and testing methodologies. Variations in sample handling, calibration, reference ranges, and assay design can influence results and complicate comparisons between testing platforms. Certain immunoprotein concentrations can also be affected by multiple diseases and physiological conditions, requiring careful clinical interpretation. Manufacturers and laboratories must therefore maintain rigorous quality assurance, proficiency testing, and standardized procedures. As increasingly complex biomarker panels are introduced, demonstrating clinical validity and obtaining regulatory approval while maintaining rapid turnaround times can further increase development and operational complexity.
In October 2025, major diagnostic manufacturers continued advancing standardized automated immunoassay and quality-control technologies, reflecting industry efforts to improve consistency and reliability across increasingly complex protein-based diagnostic testing workflows.
Immunoprotein Diagnostic Testing Market Segmental Analysis
By Product Type
Kits & Reagents Dominated the Market with 58.9% Share in 2025
The kits & reagents segment accounted for the largest share of the global immunoprotein diagnostic testing market at 58.9% in 2025, driven by their recurring utilization across routine diagnostic procedures and immunoprotein assays. Kits and reagents are essential for detecting and measuring specific proteins associated with diseases, immune responses, and other clinical conditions. Increasing diagnostic testing volumes, expanding laboratory infrastructure, growing prevalence of chronic and infectious diseases, and continuous introduction of advanced assay kits continue to reinforce the segment's dominant market position.
Request Customization to receive a tailored report.
By Technology
Chemiluminescence Assay is Projected to Register the Fastest Growth at a CAGR of 7.48%
The chemiluminescence assay segment is projected to register the fastest growth in the immunoprotein diagnostic testing market at a CAGR of 7.48% during the forecast period, supported by increasing demand for sensitive, accurate, and automated diagnostic testing technologies. Chemiluminescence assays enable efficient detection and quantification of biomarkers across numerous clinical applications while supporting high-throughput laboratory workflows. Increasing adoption of automated immunoassay platforms, growing diagnostic testing volumes, and rising demand for rapid and reliable laboratory results continue to strengthen the adoption of chemiluminescence-based testing.
By Application
Oncology Dominated the Market with 27.4% Share in 2025
The oncology segment accounted for the largest share of the global immunoprotein diagnostic testing market at 27.4% in 2025, supported by increasing utilization of protein biomarkers for cancer detection, disease monitoring, treatment assessment, and clinical decision-making. Immunoprotein testing helps identify and measure biomarkers associated with different malignancies and supports various stages of cancer management. Growing cancer diagnostic volumes, increasing emphasis on early disease detection, advancements in biomarker-based testing, and expanding adoption of personalized treatment approaches continue to reinforce the oncology segment's leading market position.
By End User
Diagnostic Laboratories Dominated the Market with 48.7% Share in 2025
The diagnostic laboratories segment accounted for the largest share of the global immunoprotein diagnostic testing market at 48.7% in 2025, driven by high testing volumes and widespread availability of specialized immunoassay technologies across centralized and independent laboratories. Diagnostic laboratories perform a broad range of immunoprotein tests for oncology, infectious diseases, autoimmune disorders, endocrine conditions, and other clinical applications. Increasing demand for specialized diagnostic services, expansion of laboratory networks, growing adoption of automated testing platforms, and rising requirements for accurate and high-throughput testing continue to support the segment's dominant position.
Speak to an Analyst to discuss market opportunities.
Immunoprotein Diagnostic Testing Market Regional Outlook
North America Immunoprotein Diagnostic Testing Market Analysis
North America dominated the immunoprotein diagnostic testing market with the largest 38.5% market share in 2025, representing a market value of USD 4 billion. The region is projected to grow at a CAGR of 6.42% during the forecast period. Its leadership is supported by advanced healthcare infrastructure, extensive diagnostic laboratory networks, increasing prevalence of chronic and immune-related disorders, and widespread adoption of sophisticated diagnostic technologies. Immunoprotein testing is used to measure specific proteins associated with immune responses, inflammation, infections, and various disease conditions. Growing emphasis on early disease detection and personalized treatment is strengthening testing demand. Continued investment in laboratory automation and diagnostic technologies supports North America's position in the global immunoprotein diagnostic testing market.
United States Immunoprotein Diagnostic Testing Market Insights
The United States is an important contributor to the immunoprotein diagnostic testing market due to its sophisticated healthcare infrastructure, extensive clinical laboratory network, strong diagnostic technology industry, and high utilization of advanced laboratory testing. Immunoprotein assays are used across hospitals, diagnostic laboratories, research institutions, and specialty clinics for evaluating immune function, inflammatory conditions, infections, and other disorders. Increasing adoption of automated immunoassay platforms enables laboratories to improve testing throughput, accuracy, and operational efficiency. Growing emphasis on preventive healthcare and earlier disease identification is also supporting diagnostic demand. Continued development of biomarkers, laboratory automation, and precision diagnostics supports growth of the country's immunoprotein diagnostic testing market.
Canada Immunoprotein Diagnostic Testing Market Insights
Canada contributes to the immunoprotein diagnostic testing market through its established healthcare system, expanding diagnostic capabilities, and growing demand for laboratory testing associated with chronic, inflammatory, and immune-mediated conditions. Hospitals and clinical laboratories utilize immunoprotein assays to support disease diagnosis, patient monitoring, and treatment decisions. Increasing adoption of automated laboratory equipment is helping healthcare providers improve test processing efficiency and consistency. Growing awareness of early diagnosis and preventive healthcare is further supporting utilization of specialized diagnostic tests. Research institutions also contribute to development and evaluation of emerging biomarkers and testing technologies. Continued modernization of clinical laboratories supports long-term development of Canada's immunoprotein diagnostic testing market.
Unlock Regional Insights to access country-level data, & regional trends.
Asia-Pacific Immunoprotein Diagnostic Testing Market Analysis
Asia-Pacific is the fastest-growing region in the immunoprotein diagnostic testing market and is expected to expand at a CAGR of 8.12% during the forecast period. The region accounted for 22.7% of the global market in 2025, representing a market value of USD 2.36 billion. Growth is supported by expanding healthcare infrastructure, increasing diagnostic awareness, large patient populations, and rising prevalence of chronic and immune-related conditions. Development of hospitals and diagnostic laboratories is improving access to specialized immunoprotein testing across major markets. Increasing healthcare expenditure and adoption of automated diagnostic platforms are further supporting market expansion. Growing domestic diagnostic manufacturing capabilities and laboratory modernization support strong development of the immunoprotein diagnostic testing market across Asia-Pacific.
Japan Immunoprotein Diagnostic Testing Market Insights
Japan is an important contributor to the immunoprotein diagnostic testing market through its advanced healthcare system, sophisticated diagnostic infrastructure, aging population, and strong medical technology capabilities. Hospitals and laboratories use immunoprotein assays to evaluate inflammatory conditions, immune disorders, infections, and other clinical conditions requiring measurement of specific proteins. Growing requirements for effective management of chronic diseases are supporting demand for accurate and reliable diagnostic technologies. Japan's expertise in laboratory automation, medical devices, and analytical technologies supports development of efficient immunoassay platforms. Increasing integration of laboratory information systems further improves diagnostic workflows. Continued healthcare innovation strengthens Japan's contribution to the Asia-Pacific immunoprotein diagnostic testing market.
China Immunoprotein Diagnostic Testing Market Insights
China plays a significant role in the immunoprotein diagnostic testing market due to its large patient population, expanding healthcare infrastructure, rapidly developing diagnostic industry, and increasing adoption of advanced laboratory technologies. Hospitals and diagnostic centers are strengthening testing capabilities to support diagnosis and monitoring of inflammatory, infectious, immune-mediated, and chronic diseases. Expansion of laboratory infrastructure beyond major metropolitan areas is improving access to specialized testing services. Domestic diagnostic manufacturers are also developing immunoassay analyzers, reagents, and related laboratory products. Increasing healthcare expenditure and growing emphasis on earlier disease detection are supporting testing volumes. Continued healthcare modernization reinforces China's importance within the Asia-Pacific immunoprotein diagnostic testing market.
Europe Immunoprotein Diagnostic Testing Market Analysis
Europe accounted for 28.4% of the global immunoprotein diagnostic testing market in 2025, reaching a market value of USD 2.95 billion. The region is anticipated to grow at a CAGR of 6.18% during the forecast period. Market development is supported by established healthcare systems, extensive clinical laboratory infrastructure, growing chronic disease burden, and continued adoption of advanced diagnostic technologies. Immunoprotein testing supports diagnosis and monitoring across multiple clinical areas by providing information regarding immune responses and disease-related biomarkers. Increasing automation of laboratory processes is improving testing efficiency and standardization. Growing emphasis on personalized medicine and early diagnosis is also expanding applications, supporting development of the immunoprotein diagnostic testing market across Europe.
Germany Immunoprotein Diagnostic Testing Market Insights
Germany is an important contributor to the immunoprotein diagnostic testing market in Europe due to its advanced healthcare infrastructure, strong diagnostics industry, extensive clinical laboratory network, and established biomedical research capabilities. Hospitals and diagnostic laboratories utilize immunoprotein assays for evaluating immune function, inflammatory diseases, infections, and other medical conditions. Increasing adoption of automated analyzers helps laboratories process larger testing volumes while maintaining consistent performance. Germany's strong life sciences and medical technology ecosystem also supports development of diagnostic instruments, reagents, biomarkers, and laboratory technologies. Growing emphasis on precise diagnosis and efficient disease management further supports adoption. Continued diagnostic innovation strengthens Germany's position within the European immunoprotein diagnostic testing market.
United Kingdom Immunoprotein Diagnostic Testing Market Insights
The United Kingdom contributes to the immunoprotein diagnostic testing market through its established healthcare system, strong clinical research ecosystem, diagnostic laboratory capabilities, and increasing emphasis on early disease identification. Immunoprotein tests are utilized across clinical laboratories and hospitals to support diagnosis and monitoring of immune-mediated, inflammatory, infectious, and other conditions. Development of automated testing platforms is improving laboratory efficiency and supporting standardized diagnostic workflows. Research into biomarkers and precision medicine is also broadening potential applications for protein-based diagnostic testing. Increasing integration of diagnostic information into broader patient management processes further supports adoption. Continued clinical research and laboratory modernization support the United Kingdom's contribution to the European immunoprotein diagnostic testing market.
Latin America Immunoprotein Diagnostic Testing Market Analysis
Latin America represented 6.1% of the global immunoprotein diagnostic testing market in 2025, with a market value of USD 0.63 billion. The region is expected to register a CAGR of 6.71% during the forecast period. Growth is supported by improving healthcare infrastructure, expansion of diagnostic laboratory networks, increasing awareness of early disease detection, and rising adoption of automated diagnostic technologies. Growing requirements for diagnosing chronic, inflammatory, infectious, and immune-related diseases are creating demand for specialized immunoprotein assays. Investments in hospital and laboratory modernization are improving access to advanced diagnostic platforms. Increasing availability of diagnostic reagents and analyzers further supports testing capabilities, contributing to continued expansion of the immunoprotein diagnostic testing market across Latin America.
Brazil Immunoprotein Diagnostic Testing Market Insights
Brazil is an important contributor to the immunoprotein diagnostic testing market in Latin America due to its large healthcare system, substantial patient population, expanding private diagnostic laboratory sector, and increasing adoption of advanced testing technologies. Hospitals and laboratories use immunoprotein assays to support diagnosis and monitoring of inflammatory, infectious, autoimmune, and other health conditions. Growing laboratory automation is improving processing capacity and enabling more efficient handling of diagnostic workloads. Expansion of healthcare services and increasing awareness of preventive testing are also supporting demand. Continued development of clinical laboratories, adoption of advanced analyzers, and investment in healthcare infrastructure reinforce Brazil's importance within the regional immunoprotein diagnostic testing market.
Middle East and Africa Immunoprotein Diagnostic Testing Market Analysis
The Middle East and Africa accounted for 4.3% of the global immunoprotein diagnostic testing market in 2025, representing a market value of USD 0.45 billion. The region is projected to expand at a CAGR of 6.29% during the forecast period. Market development is supported by improving healthcare infrastructure, expansion of diagnostic laboratories, increasing chronic disease management requirements, and growing access to advanced testing technologies. Hospitals and laboratories are adopting modern diagnostic systems to improve disease detection and patient monitoring. Development of automated laboratory infrastructure is also increasing the availability and efficiency of specialized testing. Continued investment in hospitals and diagnostic services supports long-term development of the immunoprotein diagnostic testing market across the region.
UAE (United Arab Emirates) Immunoprotein Diagnostic Testing Market Insights
The UAE contributes to the immunoprotein diagnostic testing market within the Middle East and Africa through its modern healthcare infrastructure, sophisticated diagnostic laboratories, expanding preventive healthcare services, and strong adoption of advanced medical technologies. Hospitals and laboratories utilize immunoprotein assays to support assessment of inflammatory, infectious, immune-related, and other clinical conditions. Increasing adoption of automated diagnostic platforms enables healthcare providers to improve testing efficiency and laboratory workflows. The country's emphasis on advanced healthcare and early disease identification is also supporting demand for specialized laboratory services. Continued investment in diagnostic infrastructure, medical technology, and laboratory automation strengthens the UAE's role in the regional immunoprotein diagnostic testing market.
Immunoprotein Diagnostic Testing Market Competitive Landscape
The immunoprotein diagnostic testing market is slightly fragmented and competitive, with major companies such as Abbott Laboratories, Roche, Thermo Fisher Scientific, Danaher Corporation, Siemens Healthineers, Bio-Rad Laboratories, DiaSorin, bioMérieux, Fujirebio, and QuidelOrtho competing through automated immunoassay systems, protein biomarker testing, and integrated diagnostic platforms. Competition is increasingly driven by high-sensitivity assays, multiplex testing, laboratory automation, point-of-care technologies, and disease-specific biomarkers for autoimmune disorders, cancer, cardiovascular diseases, infections, and neurological conditions. Companies are focusing on expanding assay menus and developing faster and more accessible protein-based diagnostic tests.
List of Key and Emerging Players in Immunoprotein Diagnostic Testing Market
Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
PerkinElmer Inc.
Bio-Rad Laboratories, Inc.
Aurora Biomed Inc.
Tecan Trading AG
Promega Corporation
Charles River Laboratories
Creative Biolabs
ACROBiosystems
DiaSorin S.p.A.
Enzo Biochem Inc.
BIOMÉRIEUX
Abcam Limited
Beckman Coulter, Inc.
Key Industry Developments
May 2025: Abbott expanded its immunoprotein diagnostic testing portfolio by advancing automated immunoassay platforms and laboratory diagnostic solutions. The developments focused on improving testing accuracy, workflow efficiency, and disease detection capabilities.
June 2025: Roche Diagnostics expanded its immunodiagnostics portfolio by enhancing electrochemiluminescence-based testing solutions for clinical applications. The company focused on improving biomarker detection, diagnostic precision, and laboratory automation.
July 2025: Siemens Healthineers expanded its immunoprotein diagnostic solutions by advancing automated laboratory systems and immunoassay technologies. The developments focused on improving diagnostic workflows and supporting personalized healthcare.
September 2025: Danaher expanded its diagnostic technologies portfolio through advancements in immunoassay platforms and clinical testing solutions. The company focused on improving disease monitoring, biomarker analysis, and laboratory efficiency.
Report Scope
Comments
No comment